4Singer DE,Albers GW,Dalen JE,et al.Antithrombotic therapy in atrial fibrillation:American college of chest physicians evidence-based Clinical practice guidelines(8th edition)[J].Chest,2008,133(Suppl 6):546-592.
5Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation.Analysis of pooled data from five randomized controlled trials[J].Arch Intern Med,1994,154(13):1449-1457.
6Wadelius M,Chen LY,Eriksson N,et al.Association of warfarin dose with genes involved in its action and metabolism[J].Hum Genet,2007,121(1):23-24.
7Jonas DE,Mc-Leod HL.Genetic and clinical factors relating to warfarin dosing[J].Trends Pharmacol Sci,2009,30(7):375-386.
9Fuster V,Ryden LE,Cannom DS,et al.ACC/AHA/ESC 2006 guidelines for the management of patients with artrial fibrillation:a report of the American college of cardiology/American heart association task force on practice guidelines and the european society of cardiology committee for practice guidelines(writing committee to revise the 2001 guidelines for the management of patients with artrial fibrillation):developed in collaboration with the European Heart Rhythm Association and the heart rhythm society[J].Circulation,2006,114(7):257-354.
10Oral H,Chugh A,Ozaydin M,et al.Risk of thromboembolic events after percutaneous left atrial radiofrequency ablation of atrial fibrillation[J].Circulation,2006,114(8):759-765.
9Eric L Eisenstein, DBA,Kevin J. Anstrom, PhD,David F. Kong, MD,Linda K. Shaw, MS,Robert H. Tuttle, MSPH,Daniel B. Mark, MD, MPH,Judith M. Kramer, MD, MS,Robert A. Harrington, MD,David B. Matchar, MD,David E. Kandzari, MD 1,Eric D. Peterson, MD, MPH,Kevin A. Schulman, MD,Robert M. Califf, MD,李呈亿（译）,David E. Kandzari, MD.氯吡格雷的使用与药物洗脱支架植入后远期临床结果[J].美国医学会杂志（中文版）,2007,26(3):131-139. 被引量：59
10Fuster V, Ryden LE, Asinger RW, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and the
4European Heart Rhythm Association, European Association for Cardio- Thoracic Surgery, Camm A J, et al. Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European Society of Cardiology(ESC) [J]. Europace,2010,12(10) : 1360.
5四川美康医药软件.药物临床信息参考[M].四川:四川科学出版社,2007:1076.
6Sehelleman H, Limdi NA, Kimmel SE. Ethnic differences in warfarin ma- intenance dose requirement and its relationship with genetics [ J ]. Phar- macogenomics, 2008,9 ( 9 ) : 1331 - 1346.
7Namazi S, Azarpira N, Hendijani F, et al. The impact of genetic polymor- phisms and patient characteristics on warfarin dose requirements : a cross- sectional study in Iran[ J]. Clin Ther,2010,32(6) :1050 -1060.
8Maurice CB, Barua PK, Simses D, et al. Comparison of assay systems for warfarin-related CYP2 C9 and VKORC 1 genotyping [ J ]. Clin Chim Acta, 2010,411 (13/14) :947 -954.
10Choi JR, Kim JO, Kang DR, et al. Proposal of pharmacogenetics-based warfarin dosing algorithm in Korean patients [ J ]. J HumGenet,2011,56: 290 - 295.
